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Safety evaluation of clinical gene therapy using hepatocyte growth
factor to treat peripheral arterial disease
Morishita R, Aoki M, Hashiya N, et al. Hypertension 2004;44:203-9.
Conclusion:Hepatocyte growth factor (HGF) gene transfer may be a
useful therapy for critical limb ischemia.
Summary: HGF has potent angiogenic activity. The authors investi-
gated the efficacy and safety of HGF plasmid DNA in patients with critical
limb ischemia. This was a prospective open-labeled clinical trial. NakedHGF
plasmid DNA was injected intramuscularly in six patients with critical limb
ischemia. Critical limb ischemia was secondary to atherosclerosis in three and
Buergers’ disease in three. Limbs were Fontaine class III or IV. The primary
endpoint was improvement of ischemic symptoms 12 weeks after transfec-
tion. Safety was also evaluated.
In no patient were there significant complications or adverse effects
detected secondary to gene transfer. Serum HGF concentration did not
change throughout therapy in any patient. A reduction of 1 cm in visual
analog pain scale was observed in five of six patients. In five patients, the
ankle brachial index increased 0.1. Eight of 11 ischemic ulcers in four
patients were reduced in long diameter by 25%.
Comment: Patients with critical limb ischemia have a poor prognosis.
In that regard, the outcome of this initial study is encouraging. However, it
is known that there is a large placebo effect in drug treatment of patients with
critical limb ischemia. This study should be regarded as preliminary data
suggesting safety of the procedure. It has far too few patients to suggest
efficacy or provide conclusive data about safety.
Screening for abdominal aortic aneurysm: A best evidence systematic
review for the US Preventive Services Task Force
Fleming C, Whitlock EP, Beil TL, et al. Ann Intern Med 2005;142:203-11.
Conclusion: An invitation to attend an abdominal aortic aneurysm
(AAA) screening study reduces AAA-related mortality in men aged 65 to 75
years.
Summary: The authors reviewed evidence pertaining to screening for
AAA and the effectiveness of such screening in reducing AAA mortality. A
review of pertinent studies was performed by investigators from the Oregon
Evidence-Based Practice Center in Portland, Ore, in collaboration with the
United States Preventative Services Task Force and the Agency for Health-
care Research and Quality, Rockville, Md. The purpose was to examine the
benefits and harms of population-based AAA screening. The authors
searched the literature from 1994 to July 2004 by usingMedline, a reference
list of articles, expert suggestions, and supplementation by the Cochrane
library. They sought to identify randomized trials of AAA screening, includ-
ing data on treatment events from randomized trials and data on adverse
events resulting from screening. Studies were then abstracted, reviewed, and
rated for quality by using predefined criteria.
Four population-based, randomized, controlled trials of AAA screen-
ing were identified. All trials identified potential participants aged65 years
through the use of regional health directories or population registries. The
trials included the Multicentre Aneurysm Screening Study (MASS) and the
Chichester screening study, both from the United Kingdom, and screening
studies from Denmark and western Australia. There were more than
125,000 total participants. Only the Chichester trial included women.
A meta-analysis determined that an invitation to attend a screening was
associated with reduction in AAA-related mortality (odds ratio, 0.57; 95%
confidence interval [CI], 0.45 to 0.74). There was no significance difference
in all-cause mortality (odds ratio, 0.98; 95% CI, 0.95 to 1.02) and no
significant difference in aneurysm-related mortality for women in the one
study that included women. Screening was not associated with significant
physical or psychologic harm. The authors found no evidence to support
additional screening studies beyond the initial study should the initial study
fail to reveal an aneurysm.
The odds ratio for finding an AAA of 4 cm, when adjusted for other
risk factors, increased by 1.71 (95% CI, 1.61 to 1.81) for each 7-year age
increment. Smoking was associated with a 3 to 5 times increase in AAA
prevalence across all age groups and an increased risk for AAA-related
mortality. If only men with a history of smoking (defined as lifetime
consumption of 100 cigarettes) were invited for screening, they would
account for 89% of the expected reduction in AAA-related mortality for
population screening of all men 65 to 74 years of age.
Comment: This is the most comprehensive analysis of potential effec-
tiveness for AAA screening that has been published. It is more conservative
and restrictive than that suggested by the Society for Vascular Surgery (SVS)
and Society for Vascular Medicine and Biology (SVMB). The SVS/SVMB
screening recommendations for AAA screening are for all men age 60 to 85
years, women age 60 to 85 years with cardiovascular risk factors, and men
and women aged 50 years with a family history of AAA (JVS 2004;
39:267-9). Recommendations in the current article are derived from a more
stringent analysis than the recommendations of the SVS/SVMB. As such,
the current recommendations of theUS Preventative Services Task Force are
likely to have more influence with Medicare and other insurance payers than
the SVS/SVMB recommendations.
Comparison of extra-anatomic bypass grafting with angioplasty for
atherosclerotic disease of the supra-aortic trunks
Modarai B, Ali T, Dourado R, et al. Br J Surg 2004;91:1453-7.
Conclusion: Treatment of supra-aortic trunk occlusive disease with
extra-anatomic bypass compared with angioplasty results in better patency
with comparable complication rates.
Summary: The authors sought to compare initial success and out-
comes of treatment of symptomatic stenosis of the supra-aortic trunks
(innominate and common carotid arteries and subclavian arteries) with
either angioplasty and stenting or extra-anatomic surgical bypass. Data was
obtained from a prospectively maintained database from a single academic
medical center in London between 1993 and 2003. Data on presentation,
initial success, complications, and long-term patency were analyzed.
During the study period, 35 extra-anatomic bypasses were performed
comprising 13 carotid-carotid bypasses, 14 carotid-subclavian bypasses, 2
carotid-axillary bypasses, 3 axillary-axillary bypasses, 2 subclavian-subclavian
bypasses, and 1 subclavian-axillary bypass. All but three of the extra-ana-
tomic bypass grafts were prosthetic. One prosthetic bypass occluded on the
second postoperative day and underwent successful thrombectomy. One
additional graft occluded at 19 years. There were two temporary neuroprax-
ias of the brachial plexus. Secondary patency at 5 years was 97% (34 of 35).
No limbs were amputated and no patient had a stroke. There were 41
attempted angioplasties. Attempted angioplasty for six subclavian artery
occlusions was unsuccessful. Twenty-seven (82%) of 33 successful angioplas-
ties remained patent at a mean follow-up of 4 years.
Comment:The study documents exceptional patency of surgical extra-
anatomic bypass for supra-aortic trunk occlusive disease. However, patency
in this study was based on clinical symptoms, signs, and Doppler pressures.
It is therefore possible, as the authors admit, that asymptomatic graft and
angioplasty occlusions were missed. The results of this study are in line with
comparisons of surgical reconstructions and catheter-based interventions at
many sites. Despite the more favorable durability of surgical versus catheter-
based reconstructions, many patients and many physicians are willing to
accept decreased long-term patency to have diminished short-term proce-
dure-related morbidity. An assessment of periprocedure and long-term
quality of life in these patients would have been a useful addition to this
study.
Negative D-dimer result to exclude recurrent deep venous thrombosis:
A management trial
Rathbun SW,Whitsett TL, Raskob GE. Ann InternMed 2004;141:839-45.
Conclusion: Measurement of plasma D-dimer can provide a simple
method to exclude acute recurrent deep venous thrombosis (DVT) in
patients with leg symptoms.
Summary: All diagnostic tests to exclude acute recurrent DVT have
limitations. This study sought to test the safety of withholding additional
diagnostic testing and heparin treatment in 300 consecutive inpatients and
outpatients with previous DVT who presented with new leg symptoms. The
study was conducted at an academic medical center in the United States.
Heparin therapy was withheld and no further diagnostic testing for DVTwas
performed in patients with negative D-dimer test results. Patients underwent
a compression ultrasound examination if the D-dimer test result was posi-
tive. The primary outcome measure was a diagnosis of symptomatic venous
thromboembolism (VTE) confirmed by objective testing during the
3-month follow-up period.
D-dimer test results were negative at presentation in 134 patients (45%)
and positive in 166 patients. Of the 166 patients with positive D-dimers, an
ultrasound examination documented acute DVT in 54 patients. Ultrasound
test results were normal in 79 of the 166 patients with positive D-dimer and
inconclusive in 33 patients. In the 134 patients with negative D-dimer at
presentation, after 3 months one episode (0.75%) of VTE was confirmed
(95% confidence interval [CI], 0.02% to 4.09%). VTE could not be defini-
tively excluded in 5 patients in follow-up, and 1 patient died. If all of these
patients were classified as having VTE, the incidence of VTE during the
3-month follow-up period with initial negative D-dimer testing would be 6%
(95% CI, 2.6% to 11.4%). Overall, 56% of patients in the negative D-dimer
group were receiving warfarin at the time of presentation.
Comment: The diagnosis of recurrent DVT is often difficult, especially
when old residual venous thrombus is present. This study suggests a negative
D-dimer in patients with suspected recurrent DVT may allow heparin
therapy to be safely withheld. This study has a number of limitations,
however. Many of the patients in this study were on warfarin therapy, and we
don’t know the effects of warfarin on D-dimer testing. In addition, patients
could have had recurrent VTE that could not be diagnosed by available
diagnostic techniques. However, with respect to management, it does
appear to be safe to withhold heparin in patients with possible recurrent
DVT who have a negative D-dimer test.
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